Sutro Biopharma (STRO) Corporate presentation summary

Platform innovation and technology

• Proprietary cell-free platform enables site-specific conjugation and click chemistry for uniform, stable ADCs, enhancing precision, versatility, and scalability from discovery to commercial scale.

• Platform optimizes antibody, linker, and payload components to expand the therapeutic window, minimize toxicity, and maximize efficacy.

• Industry-leading ADC exposure achieved, resulting in better pharmacokinetics and reduced systemic toxicity in preclinical models.

Pipeline and clinical development

• Advancing a differentiated pipeline of single- and dual-payload ADCs targeting complex tumor antigens, with three INDs planned in three years.

• Lead programs include STRO-004 (TF-targeting, Phase 1 ongoing, initial data mid-2026), STRO-006 (ITGB6-targeting, IND in 2026), and STRO-227 (PTK7 dual-payload, IND in 2026).

• Well-capitalized with cash runway into at least Q2 2028.

Preclinical and clinical data highlights

• STRO-004 demonstrates 50x preclinical exposure over approved TF ADCs, robust anti-tumor activity, and a favorable safety profile with reduced bleeding risk.

• STRO-006 shows superior activity and duration of response versus competitor ADCs in ITGB6-expressing models, with high selectivity and tolerability.

• Dual-payload ADCs overcome resistance and drive tumor regression in preclinical models, with tolerability benchmarks matching single-payload ADCs.